News Articles on Forest Laboratories, Inc.

Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation

NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and its wholly-owned subsidiary, Forest Laboratories Holdi
http://www.bioportfolio.com/news/Forest_Laboratories_and_H._Lundbeck_A%2FS_Enter.html - Friday July 10 2009

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 First Quarter Earnings

NEW YORK, July 6, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutica
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Sets_Date_and.html - Monday July 6 2009

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization

Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates in Adult Patients Hospitalized for Moderate to Severe CABP

http://www.bioportfolio.com/news/Forest_Laboratories_Announces_Positive_Top-line.html - Friday June 19 2009

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits --

C
http://www.bioportfolio.com/news/Ironwood_and_Forest_Present_Additional_Positive.html - Sunday May 31 2009

Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide

- Data to be presented at Digestive Disease Week 2009 -

CAMBRIDGE, Mass. and NEW YORK, May 12, 2009 /PRNewswire-FirstCall/ -- Ironw
http://www.bioportfolio.com/news/Ironwood_and_Forest_to_Present_Additional_Phase.html - Tuesday May 12 2009

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

Company Provides Fiscal Year 2010 EPS Guidance in the Range of $3.45-$3.55 Per Share

NEW YORK, April 21 /PRN
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Reports_Fiscal_Year.html - Tuesday April 21 2009

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)

NEW YORK and SAN DIEGO, April 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB)
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._and_Cypress_Bioscience%2C.html - Monday April 20 2009

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Fourth Quarter Earnings

NEW YORK, April 6, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutic
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Sets_Date_and.html - Monday April 6 2009

Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents

NEW YORK, March 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Announces_FDA_Approval.html - Friday March 20 2009

USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R)

NEW YORK, March 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) Forest Laboratories Holdings, Ltd., Merz Pharma GmbH &
http://www.bioportfolio.com/news/USPTO_Issues_Notice_of_Final_Determination_for.html - Tuesday March 10 2009

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)

NEW YORK and SAN DIEGO, March 6, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) a
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._and_Cypress_Bioscience%2C.html - Friday March 6 2009

Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program

NEW YORK, March 6 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. today announced after co
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._and_Laboratorios.html - Friday March 6 2009

Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government

NEW YORK, Feb. 26, 2009 /PRNewswire-FirstCall/ --Forest Laboratories, Inc. (NYSE: FRX) today announced that a complaint filed against the Company b
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Provides_Statement_in.html - Thursday February 26 2009

Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees

NEW YORK, Jan. 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), a U.S. based pharmaceutical company, today announced that
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Reports_Q3%26apos%3B09.html - Tuesday January 20 2009

Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia

New treatment option for the estimated 6 million Americans living with this chronic, debilitating condition

NEW YORK and SA
http://www.bioportfolio.com/news/Forest_and_Cypress_Announce_FDA_Approval_of.html - Wednesday January 14 2009

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings

NEW YORK, Jan. 5, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutica
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Sets_Date_and.html - Monday January 5 2009

Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression

NEW YORK and PARIS, Dec. 22, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced that
http://www.bioportfolio.com/news/Pierre_Fabre_Medicament_and_Forest_Laboratories.html - Monday December 22 2008

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) to
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._and_Cypress_Bioscience%2C.html - Monday December 8 2008

Forest Laboratories Responds To Unsolicited Mini-Tender Offer

NEW YORK, Dec. 3, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced that it has been notified of an unsolicited
http://www.bioportfolio.com/news/Forest_Laboratories_Responds_To_Unsolicited.html - Wednesday December 3 2008

USPTO Confirms Validity of Bystolic(R) Patent

NEW YORK, Nov. 24, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Patent and Trademark Office (
http://www.bioportfolio.com/news/USPTO_Confirms_Validity_of_Bystolic%28R%29.html - Monday November 24 2008

Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA

New Data on Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in Development for Complicated Skin and Skin Structure Infections (cSSSI) and Co
http://www.bioportfolio.com/news/Positive_Study_Results_for_Ceftaroline_Phase_III.html - Monday October 27 2008

Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes

NEW YORK and SAN DIEGO, Oct. 23, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Phenomix Corporation today announced that
http://www.bioportfolio.com/news/Phenomix_and_Forest_Laboratories_to_Collaborate.html - Thursday October 23 2008

Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80

NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Reports_Fiscal_Second.html - Tuesday October 21 2008

FDA Defers Final Action on milnacipran New Drug Application

NEW YORK and SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) (the &q
http://www.bioportfolio.com/news/FDA_Defers_Final_Action_on_milnacipran_New_Drug.html - Monday October 20 2008

Forest Laboratories, Inc. Appoints Frank Murdolo, Vice President - Investor Relations

NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that it has appointed Frank Murdolo, Vice Pr
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Appoints_Frank_Murdolo%2C.html - Monday September 15 2008

USPTO Office Action in the Reexamination of U.S. Patent No. 6,545,040

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that an Office Action in the Reexamination of
http://www.bioportfolio.com/news/USPTO_Office_Action_in_the_Reexamination_of_U.S..html - Thursday September 4 2008

Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NEW YORK, Sept. 3 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. today announced results from
http://www.bioportfolio.com/news/Phase_III_Clinical_Studies_of_Aclidinium_Bromide.html - Wednesday September 3 2008

New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation

CHICAGO, July 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) presented today positive Phase III data of a once-daily extend
http://www.bioportfolio.com/news/New_Data_Highlight_Positive_Results_of_Namenda%28R%29.html - Wednesday July 30 2008

Forest Laboratories, Inc. Reports Fiscal First Quarter 2009 Earnings Per Share of $0.79, Including $0.08 per Share Charge for Agreement Termination

NEW YORK, July 22 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, t
http://www.bioportfolio.com/news/Forest_Laboratories%2C_Inc._Reports_Fiscal_First.html - Tuesday July 22 2008